What is HC Wainwright’s Forecast for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat expects that the company will earn ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.

TARS has been the topic of several other research reports. Guggenheim reissued a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $43.55 on Friday. The firm’s 50 day moving average price is $51.14 and its two-hundred day moving average price is $43.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28. The stock has a market cap of $1.66 billion, a PE ratio of -11.43 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after purchasing an additional 420,057 shares during the last quarter. Creative Planning bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $362,000. Vestal Point Capital LP bought a new stake in Tarsus Pharmaceuticals during the third quarter worth about $7,565,000. Jennison Associates LLC grew its stake in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after purchasing an additional 321,552 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $763,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.